Jonathan Hepple
Board member
Brain Repair and Imaging in the Neural Systems unit
Clanotech
Sweden
Biography
Jonathan Hepple, Ph D, Venture investor in life science companies since 1998. Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Enobia Pharmaceuticals, GeminX Pharmaceuticals, Cytochroma, Forward Pharma and Zealand Pharmaceuticals. Also Partner at Seroba Kernel Life Sciences, a European venture firm, investing in biotech and medtech. Current board seats include Axelar AB, Clanotech AB, Covagen AG and Opsona Therapeutics.
Research Interest
Life Sciences
